The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy.
Rapid improvement in glycaemic control with GLP-1 receptor agonist (RA) therapy has been reported to be associated with significant progression of diabetic retinopathy. This deterioration is transient, and continuing GLP-1 RA treatment is associated with reversal of this phenomenon. Pre-existent maculopathy, higher grade of retinopathy and longer duration of diabetes may be risk factors for persistent deterioration.
Department of Diabetes and Endocrinology, University Hospital of North Staffordshire NHS Trust, Trent Building, Stoke-on-Trent ST4 6QG, United Kingdom. Electronic address: laks.varadhan@gmail.com.
Lakshminarayanan
L
Varadhan
Department of Diabetes and Endocrinology, University Hospital of North Staffordshire NHS Trust, Trent Building, Stoke-on-Trent ST4 6QG, United Kingdom; Department of Ophthalmology, University Hospital of North Staffordshire NHS Trust, Trent Building, Stoke-on-Trent ST4 6QG, United Kingdom.
Tracy
T
Humphreys
Department of Diabetes and Endocrinology, University Hospital of North Staffordshire NHS Trust, Trent Building, Stoke-on-Trent ST4 6QG, United Kingdom.
Adrian B
AB
Walker
Department of Diabetes and Endocrinology, University Hospital of North Staffordshire NHS Trust, Trent Building, Stoke-on-Trent ST4 6QG, United Kingdom. Electronic address: george.varughese@uhns.nhs.uk.
George I
GI
Varughese
D001786:Blood Glucose / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000517:prevention & control; D003930:Diabetic Retinopathy / Q000097:blood / Q000188:drug therapy*; D018450:Disease Progression; D000077270:Exenatide; D005500:Follow-Up Studies; D052216:Glucagon-Like Peptide 1 / Q000378:metabolism; D000067757:Glucagon-Like Peptide-1 Receptor; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use*; D018027:Receptors, Glucagon / Q000819:agonists*; D012307:Risk Factors; D014688:Venoms / Q000627:therapeutic use*
D001786:Blood Glucose; D000077270:Exenatide; D052216:Glucagon-Like Peptide 1; D000067757:Glucagon-Like Peptide-1 Receptor; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D010455:Peptides; D018027:Receptors, Glucagon; D014688:Venoms; C000593833:GLP1R protein, human; C517652:hemoglobin A1c protein, human
GLP-1 agonist; Retinopathy; Screening; Transient deterioration